A Non-interventional Prospective Study of 1-st Line Treatment Approaches in OVArian Cancer Patients With HRD+ Status in Russian Federation

Active, not recruitingOBSERVATIONAL
Enrollment

400

Participants

Timeline

Start Date

June 21, 2023

Primary Completion Date

July 31, 2025

Study Completion Date

July 31, 2025

Conditions
Ovarian Cancer
Trial Locations (24)

Unknown

Research Site, Arkhangelsk

Research Site, Barnaul

Research Site, Chelyabinsk

Research Site, Grozny

Research Site, Irkutsk

Research Site, Izhevsk

Research Site, Kaliningrad

Research Site, Kaluga

Research Site, Krasnodar

Research Site, Krasnoyarsk

Research Site, Lyubertcy

Research Site, Moscow

Research Site, N.Novgorod

Research Site, Nal'chik

Research Site, Novosibirsk

Research Site, Omsk

Research Site, Saint Petersburg

Research Site, Saratov

Research Site, Sochi

Research Site, Tomsk

Research Site, Ufa

Research Site, Vladivostok

Research Site, Yakutiya

Research Site, Yaroslavl

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY